Revolution Medicines Presents Additional Strong Data on KRAS-Targeting Pancreatic Cancer Drug

Apr 22, 2026

Revolution Medicines presented additional positive clinical trial data for daraxonrasib, a next-generation KRAS-targeting drug for advanced pancreatic cancer, at the American Association of Cancer Research annual meeting in San Diego. The company shared both first-line and combination therapy data on Tuesday, building on previously reported breakthrough survival results. CEO Mark Goldsmith also presented preclinical data on RM-055, described as a novel class of catalytic inhibitors that represents the next iteration after daraxonrasib by molecularly turning off the cancer protein and blocking RAS signaling. Patient Leanna Stokes is currently enrolled in the daraxonrasib clinical trial, representing those who may benefit from this expanding class of KRAS-targeted therapies.

Daraxonrasib clinical trial results in pancreatic cancer

▪Daraxonrasib is a next generation targeted therapy for advanced pancreatic cancer.
▪Leanna Stokes is a patient in a Revolution Medicines clinical trial for daraxonrasib.
▪Revolution Medicines tested daraxonrasib earlier in pancreatic cancer.

RM-055: Next-generation catalytic RAS inhibitor development

▪Mark Goldsmith is the CEO of Revolution Medicines.
▪Revolution Medicines presented preclinical data on RM-055 at the American Association of Cancer Research annual meeting.
▪RM-055 is a compound that Revolution Medicines is developing as a next iteration after daraxonrasib.
▪Mark Goldsmith calls RM-055 a novel class of catalytic inhibitors.

Perspective of Revolution Medicines

▪Revolution Medicines characterizes daraxonrasib as showing strong clinical trial data in pancreatic cancer patients.
▪Revolution Medicines positions RM-055 as representing a next iteration beyond daraxonrasib in KRAS-targeting therapy.
▪Revolution Medicines frames its drugs as expanding evidence beyond current KRAS inhibitors.
▪Revolution Medicines presented the daraxonrasib data as building on previously reported breakthrough survival results.

Perspective of Pancreatic cancer patients

▪Pancreatic cancer patients may view daraxonrasib as a targeted therapy option for advanced disease.
▪Leanna Stokes represents pancreatic cancer patients participating in Revolution Medicines clinical trials for daraxonrasib.